Dozen health tech firms face severe penalties in Italy over illegal device trials scandal
This article was originally published in Clinica
Executive Summary
Twelve “biomedical” firms operating in Italy could face severe penalties – ostensibly a ban from supplying the national health service (SSN) – as a result of a police investigation into clinical malpractices and organised criminality centred around the unapproved trialling of angioplasty devices.